Compare Novavax Inc (NVAX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Rivian Automotive, Inc. — how do they compare? Novavax Inc trades at $8.09 (market cap $1.30B), while Rivian Automotive, Inc. trades at $17.76 (market cap $24.95B). The key difference: Rivian Automotive, Inc. is far larger — about 19.2× Novavax Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | RIVN | |
|---|---|---|
Market Cap | $1.30B | $24.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $22.45 |
52-Week Low | $6.22 | $11.64 |
Enterprise Value | $800.50M | $26.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Rivian Automotive (RIVN) trades at $17.76, up 1.75% on the day, with a neutral technical outlook and bullish moving averages. The company continues to post significant losses, with a net income margin of -63.62% in 2025, though revenue grew to $5.39 billion. Recent news highlights focus on the upcoming R2 vehicle launch and a challenging EV market environment.
Rivian's investment case hinges on successful execution of the R2 launch and path to profitability, but faces substantial risks from cash burn, competition, and macroeconomic pressures. Analyst consensus is a Buy with a $19.22 price target, suggesting moderate upside potential from current levels if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
